electroCore (NASDAQ:ECOR – Get Rating)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Thursday, March 9th, Benzinga reports.
A number of other research analysts have also commented on the company. Brookline Capital Management reiterated a “buy” rating on shares of electroCore in a research report on Thursday, January 12th. Brookline Capital Acquisition initiated coverage on electroCore in a research note on Friday, January 13th. They issued a “buy” rating on the stock.
electroCore Stock Down 1.1 %
NASDAQ ECOR traded down $0.04 during trading hours on Thursday, reaching $3.44. 32,910 shares of the company’s stock were exchanged, compared to its average volume of 21,379. electroCore has a one year low of $2.92 and a one year high of $10.50. The firm has a fifty day moving average of $1.65 and a 200-day moving average of $8.14.
Institutional Investors Weigh In On electroCore
electroCore Company Profile
electroCore, Inc engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. It develops a platform bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The company was founded by Joseph P.
Further Reading
- Get a free copy of the StockNews.com research report on electroCore (ECOR)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom PricesĀ
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.